Equillium, Inc.
Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe immuno-inflammatory diseases. Its pipeline has centered on itolizumab (EQ001), EQ504, EQ302 and earlier-stage programs, but the company has not yet commercialized a product and has paused R&D pending near-term financing needs.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDrug candidates being developed for autoimmune and immuno-inflammatory diseases.
Upfront payments, development funding, and potential future license economics from partners.
Asiakkaat
Equillium does not currently sell approved products, so its near-term counterparties are primarily pharmaceutical partners, licensors, and research collaborators rather than end patients. If its candidates are approved, the eventual customers would be physicians, hospitals, and payors in specialty autoimmune and inflammatory disease markets. The company’s commercial model depends on partnering or building a sales capability later, which it does not yet have.
Biopharma partners that fund development, license assets, or share commercialization rights.
CROs, investigators, and trial sites that execute non-clinical and clinical development work.
Physicians and hospitals that would use approved therapies in immuno-inflammatory indications.
Commercial and government payors that would influence access and reimbursement after approval.
Strategia
Equillium’s strategy is to preserve optionality around its immunology pipeline while seeking capital to restart development and advance EQ504, EQ302, and itolizumab. Management has said it may pursue equity, debt, and collaboration/licensing transactions, and if financing is not secured it may need strategic alternatives or an orderly wind-down. The company’s near-term focus is therefore financing survival rather than commercial expansion.
The company paused R&D and needs capital to continue operations and avoid strategic alternatives.
Value creation depends on progressing EQ504, EQ302, and itolizumab toward clinical and regulatory milestones.
If financing is unavailable, management may need mergers, asset transactions, or a wind-up.
Maantiede
Equillium is headquartered in the United States and its disclosed commercial rights for itolizumab cover the U.S., Canada, Australia, and New Zealand. It also has an Australian subsidiary that can receive R&D tax incentive refunds, which makes Australia relevant to cash flow and expense recognition even though the company remains development-stage. The business is therefore geographically concentrated, with operational exposure tied to U.S. capital markets and partner-dependent development activity.
Riskit
Equillium is a loss-making, clinical-stage company with no approved products, so its business model is highly dependent on financing and successful drug development. The main risks are pipeline failure, inability to raise capital, competitive pressure in crowded immunology markets, and potential loss of value if it cannot maintain Nasdaq compliance or protect its intellectual property. Because it relies on third parties for research, clinical operations, and future commercialization, execution risk is also elevated.
- Financing shortfallVaikutus: KriittinenTodennäköisyys: Korkea
The company paused R&D and says it may need to raise capital in the immediate term or pursue strategic alternatives.
Kohdistuu - Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Korkea
EQ504, EQ302, and itolizumab may not demonstrate sufficient safety, efficacy, or approvability.
Kohdistuu: Pipeline value and future revenue depend on approval
- Nasdaq listing riskVaikutus: KorkeaTodennäköisyys: Korkea
Management disclosed prior and possible future non-compliance with Nasdaq Capital Market requirements.
Kohdistuu: Delisting could impair liquidity and financing access
- Competitive displacementVaikutus: KorkeaTodennäköisyys: Kohtalainen
Multiple companies are developing therapies for the same immuno-inflammatory indications.
Kohdistuu: Competitors may reach market first or offer better profiles
- Intellectual property protectionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Weak or narrow IP could allow competitors to copy or block the company’s candidates.
Kohdistuu: Affects exclusivity and commercial value
- Third-party and cybersecurity dependenceVaikutus: KeskitasoTodennäköisyys: Matala
The company relies on CROs, data vendors, cloud systems, and manufacturing partners.
Kohdistuu: Operational disruption or data incidents could delay development
Kirjanpito
Harkinnanvaraiset erätPrior revenue came from upfront payment amortization and development funding under the Ono arrangement.
Vaikutus: Can create large quarter-to-quarter swings unrelated to product sales
Eligible Australian R&D spending is recognized as a reduction of R&D expense when recovery is probable.
Vaikutus: Affects reported operating loss and cash flow timing
Potential milestone payments exist in the Biocon license, Bioniz merger agreement, and Ariagen stock purchase agreement.
Vaikutus: Could affect future liabilities if development milestones are reached
The company’s ability to continue as a going concern depends on near-term capital raising.
Vaikutus: Can influence disclosure, valuation, and liquidity assessment
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Immunic, Inc
IMUX · Pharmaceutical Preparations
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Estrella Immunopharma, Inc.
ESLAW · Biological Products, (No Diagnostic Substances)
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Päivitetty: 24.9.2026